Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome + pomalidomide + dexamethasone for relapsed/refractory multiple myeloma
ChiCTR2500098195Phase 4Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: progression-free survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
mitoxantronepomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500098195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098195.